⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16326842 | 0.71 | — | — | |
| SCHEMBL10062393 | 0.71 | — | — | |
| SCHEMBL19978616 | 0.63 | — | — | |
| SCHEMBL25478650 | 0.60 | — | — | |
| SCHEMBL7703054 | 0.58 | — | — | |
| SCHEMBL21901832 | 0.57 | — | — | |
| SCHEMBL273428 | 0.55 | — | — | |
| SCHEMBL13041573 | 0.53 | — | — | |
| SCHEMBL1682672 | 0.53 | — | — | |
| SCHEMBL7086988 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220145339-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-05-12 | — | — | US | disclosed |
| WO-2020120420-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-06-18 | — | — | WO | disclosed |
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | disclosed |
| US-9540370-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) | 2017-01-10 | — | — | US | disclosed |
| US-9353065-B2 | Heterocyclic bridged biphenyls | BASF SE (DE) | 2016-05-31 | — | — | US | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20150274724-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| WO-2009068322-A1 | SELECTIVE INHIBITION OF POLO-LIKE KINASE 1 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENS CHAFTEN E.V. (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-2065039-A1 | Selective inhibition of Polo-like kinase 1 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008052804-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918286-A1 | Thiazolhydrazides for treatment of neurodegenerative diseases | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| WO-2007060028-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1757607-A1 | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases | Molisa GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |